ACOG - Intravaginal 5-fluorouracil for treatment of Cervical Intraepithelial Neoplasia (CIN) 2

Sponsor

American College of OB/GYN

Principal Investigator

Dr. Lisa Rahangdale, Obstetrics and Gynecology

Project Run Dates

7/1/2010 to 7/31/2013

 

Summary

Cervical cancer is the 3rd leading cause of cancer worldwide. Human papillomavirus (HPV) infection is the precursor to cervical dysplasia and cancer. Though the majority of HPV infections are cleared by the body’s immune system, cervical dysplasia that persists and progresses to Cervical Intraepithelial Neoplasia 2/3 (CIN 2/3 or moderate/severe dysplasia) requires repeated cytologic screening, biopsies or excisional/ablative therapy. The management of CIN 2 is particularly challenging as nearly half of these lesions regress, particularly in young women. However, approximately one third will persist and the remaining may progress to CIN 3. We currently are not able to predict which lesions will regress, persist, recur or advance. As a result, providers are compelled to treat women surgically since there are currently no medical therapies to promote the clearance of HPV or cervical dysplasia. Of interest, in this proposal, is topical 5% 5-fluorouracil (5-FU)as it has been described as a successful, well tolerated treatment for the prevention of recurrent disease in HIV-infected women previously treated for CIN 2/3.

 

Associated Publications and other materials

Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial via PubMed